Brown Rudnick LLP

Intellectual Property and Life Sciences

Partner

Adam Schoen is a partner and co-practice group leader of Brown Rudnick's Global Intellectual Property Practice Group and Global Life Sciences Group. Adam has been in the life sciences industry for over 20 years and has over 15 years of experience advising life sciences and medical device funds, companies, and academic institutions. Adam helps his clients build, grow, invest in, buy, and sell companies of all sizes all over the world. Adam’s practice is multidisciplinary, encompassing all aspects of patent preparation and prosecution, portfolio development, product clearance, freedom to operate analysis, intellectual property due diligence, licensing, and other agreement work.

Adam has experience developing and implementing worldwide patent strategies across the life sciences industry. He works with a variety of technologies, such as small molecule therapeutics, biologics (including gene therapies and immunotherapeutics), gene editing technology, next generation sequencing technologies, microfluidics and droplet based technologies, diagnostics (including cancer and fertility diagnostics), medical device technology (ophthalmology, cardiology, orthopedics, otolaryngology, neurology, and spine), medical imaging technology (ultrasound and OCT), mass spectrometry, and digital health products.

Prior to law school, Adam was a scientist of analytical chemistry for ArQule, a combinatorial chemistry and drug discovery company, and a scientist at Millennium Pharmaceuticals.